Skip to main content

Table 3 Genes linked to promoter regions associated with the top DMFs

From: Changes in DNA methylation profiles of myalgic encephalomyelitis/chronic fatigue syndrome patients reflect systemic dysfunctions

Gene ID CpGs Control % Patient % Difference P value F test value
LOC339166 11 75 33 − 42 6.85 × 10–3 F(1,14) = 10.03
LOC339166 8 80 46 − 34 3.78 × 10–3 F(1,14) = 12.02
ZNF876P 15 53 31 − 22 8.28 × 10–3 F(1,13) = 9.68
RAB20 5 42 25 − 17 5.20 × 10–3 F(1,16) = 10.46
NUDT14 3 38 21 − 17 5.30 × 10–3 F(1,14) = 10.87
MIR138-2 5 78 62 − 16 2.23 × 10–2 F(1,14) = 6.59
ZNF714 6 12 42 + 30 1.12 × 10–2 F(1,16) = 8.22
C8orf31 3 43 64 + 21 4.75 × 10–2 F(1,13) = 4.79
PAX8-AS1 7 65 83 + 18 3.07 × 10–2 F(1,15) = 5.69
CCDC144NL 8 58 75 + 17 3.36 × 10–2 F(1,16) = 5.41
LINC00923 4 60 76 + 16 6.79 × 10–3 F(1,17) = 9.49
WNK2 17 38 54 + 16 1.12 × 10–2 F(1,16) = 8.22
  1. For each Gene ID, there is the corresponding number of CpGs within the identifying fragment, the average percentage methylation for the control subjects and ME/CFS patients, with differences (− is hypo-methylated, + is hyper-methylated). P values and F test values (degrees of freedom in brackets) are shown